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A genetically encoded maltose biosensor was constructed, comprising maltose binding protein (MBP)
ﬂanked by a green ﬂuorescent protein (GFP2) at the N-terminus and a Renilla luciferase variant (RLuc2)
at the C-terminus. This Bioluminescence resonance energy transfer2 (BRET2) system showed a 30%
increase in the BRET ratio upon maltose binding, compared with a 10% increase with an equivalent
ﬂuorescence resonance energy transfer (FRET) biosensor. BRET2 provides a better matched Fo¨rster
distance to the known separation of the N and C termini of MBP than FRET. The sensor responded to
maltose and maltotriose and the response was completely abolished by introduction of a single point
mutation in the BRET2 tagged MBP protein. The half maximal effective concentration (EC50) was
0.37 mM for maltose and the response was linear over almost three log units ranging from 10 nM to
3.16 mM maltose for the BRET2 system compared to an EC50 of 2.3 mM and a linear response ranging
from 0.3 mM to 21.1 mM for the equivalent FRET-based biosensor. The biosensor’s estimate of maltose in
beer matched that of a commercial enzyme-linked assay but was quicker and more precise,
demonstrating its applicability to real-world samples. A similar BRET2-based transduction scheme
approach would likely be applicable to other binding proteins that have a ‘‘venus-ﬂy-trap’’ mechanism.
& 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Periplasmic binding proteins (PBPs) are a large and diverse
family of soluble proteins found in bacteria. PBPs bind a wide
range of chemical species, including carbohydrates, amino acids,
neurotransmitters, metal and other ions (Medintz and
Deschamps, 2006). Although PBPs are unrelated at the primary
sequence level they all undergo a large ligand-induced conforma-
tional rearrangement commonly referred to as the ‘venus-ﬂy-trap’
mechanism (Sharff et al., 1993, 1992; Spurlino et al., 1991). Due to
the potentially large pool of analytes that can be recognised by
members of the PBP superfamily, they have been extensively
exploited as biological recognition elements for biosensors in a
wide range of application areas including security, food and drink
quality control, environmental monitoring and health-care
(Dwyer and Hellinga, 2004). In this study, we set out to improve
the sensitivity and dynamic range of a model PBP based biosen-
sor. A biosensor is an analytical device which combines a
biological recognition element, such as a periplasmic binding
protein, to a transducer element. The use of bioluminescence
instead of ﬂuorescence as the biosensor transduction element
of the PBP based biosensor reduces the cost and complexity: þ61 2 6246 4173.
).
Y-NC-ND license.of equipment needed to read the signal and markedly lowers
the limits of detection compared with any comparable, geneti-
cally encoded biosensor.
Fehr et al. (2002) developed a genetically encoded FRET based
maltose biosensor with cyan ﬂuorescent protein (CFP) at the
N-terminus and yellow ﬂuorescent protein (YFP) at the
C-terminus of maltose binding protein (MBP). Maltose induced a
conformational rearrangement in MBP bringing the CFP and YFP
closer and increasing the energy transfer rate from the CFP donor
to the YFP acceptor. However, the output signal, the change in
FRET ratio, has a narrow dynamic range, necessitating the use of
sophisticated reading equipment and spectral deconvolution.
The narrow dynamic range of the FRET ratio response is due to
the low spectral separation between the donor and acceptor
emission spectra, which is inherent to the low Stokes shift of
both FRET components. The spectral separation between donor
and acceptor emission peaks is doubled by replacing the ﬂuor-
escent donor protein with a luciferase, converting the transduc-
tion principle to bioluminescence resonance energy transfer
(BRET) (Pﬂeger and Eidne, 2006; Pﬂeger et al., 2006). The BRET2
system consists of a Renilla luciferase (RLuc) with coelenterazine
400a (Clz400a) as substrate for the donor system and a modiﬁed
green ﬂuorescent protein (GFP2) acceptor. We previously
showed that BRET is more sensitive than FRET for measuring
proteolytic cleavage (Dacres et al., 2009a, b, 2012a) and BRET2 has
a larger Fo¨rster distance than classical FRET (Dacres et al., 2010).
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cing ligand-induced activation of GPCRs (Dacres et al., 2011)
because the 6.8 nm separation of the BRET2 donor and acceptor is
a good match to its Fo¨rster distance. We noted that the measured
distance of 6.9 nm between the FRET tagged N and C termini of MBP
of (Park et al., 2009) is almost identical to the apparent distance
between the tags on the aforementioned GPCR (Dacres et al., 2011).
BRET2 is more sensitive to movements in this range than classical
FRET (Fig. S-1, Supporting information).
We therefore predicted that substituting BRET2 donor and
acceptor pairs for FRET reporters in a PBP-based sensor (Fig. 1)
would enable a larger dynamic range in the RET output ratio with
ensuing advantages for sensitivity and precision. We chose MBP
as an initial test of this prediction because it is a well-
characterised member of the PBP superfamily and is potentially
representative of many other PBPs. We report here the develop-
ment of a novel BRET based biosensor for monitoring ligand
binding by periplasmic binding proteins, with greatly enhanced
sensitivity over earlier methods.2. Materials and methods
2.1. Construction BRET proteins
The BRET2 fusion partners RLuc2 (C124A/M185V), RLuc8
(A55T/C14A/S130A/K136R/A143M/M185V/M253L/S287L) and GFP2
were ampliﬁed and restriction cloned into a series of BRET fusion
proteins containing maltose binding protein (MBP). The W140A
mutation was introduced into pRSET GFP2-MBP-RLuc2 using site-
directed mutagenesis (Stratagene). Standard molecular biology
techniques were used with primers shown in Table S-1 (SupportingFig. 1. BRET2 transduction principle for the GFP2-MBP-RLuc2 biosensor incorpor-
ating green ﬂuorescent protein (GFP2), MBP and a variant Renilla luciferase
(RLuc2). Maltose binding causes a conformational change in the biosensor bring-
ing the BRET donor and acceptor closer and increasing the efﬁciency of energy
transfer from RLuc2 to GFP2. Clz400a¼Coelenterazine 400a.
Fig. 2. (A) Bioluminescence spectra upon the addition of 16.7 mM coelenterazine 400a
GFP2–MBP–RLuc8. 20 nm intervals were used. (B) BRET2 ratio upon the addition of 16
MBP–RLuc2 or GFP2–MBP–RLuc8 following addition of 10 ml water (grey bars) or 10 minformation). All clones were sequenced to conﬁrm their integrity
and orientation.
2.2. Expression and puriﬁcation of RET proteins
Constructs were transformed into electrocompetent BL21
(DE3) cells (Novagen). At least three independent colonies were
selected for each construct and used to perform biological
replicates. Cultures were grown up and lysed using a homoge-
niser (Avestin emulsiﬂex C3 (ATA Scientiﬁc)). The BRET2 con-
structs were afﬁnity-puriﬁed over TALON
TM
Superﬂow Metal
Afﬁnity Resin (Clontech Laboratories, Inc.) and their purity was
conﬁrmed using SDS-polyacrylamide gel electrophoresis (Fig. S-2
in Supporting information). 1 mM puriﬁed protein was used for all
BRET assays unless otherwise stated.
2.3. BRET2 detection
Spectral scans were recorded with a SpectraMax M2 plate-
reading spectroﬂuorimeter (Molecular Devices). Simultaneous
dual emission BRET measurements were carried out with a
POLARstar OPTIMA microplate reader (BMG LabTech). BRET2
measurements used the BRET2 emission ﬁlter set comprising
RLuc/CLZ400a emission ﬁlter (410 nm bandpass, 80 nm) and the
GFP2 emission ﬁlter (515 nm bandpass, 30 nm). BRET2 ratios were
calculated as ratios of integrated acceptor emission channel
intensity to integrated donor emission channel intensity.
For full experimental details, see supplementary materials and
methods (Supporting information).3. Results and discussion
3.1. BRET comparisons
3.1.1. BRET intensity
Based on recent ﬁndings (Dacres et al., 2010) BRET2 provides
the best matched Fo¨rster distance to the known separation of the
N and C termini of MBP (Fig. S-1, Supplementary information)
(Park et al., 2009). However, BRET2 has a low quantum yield and
rapid decay kinetics when used with the Clz400a substrate
(Pﬂeger and Eidne, 2006). However, it was recently shown that
the sensitivity of the BRET2 assay can be signiﬁcantly improved by
use of RLuc mutants (e.g., RLuc2 and RLuc8) with improved
quantum yields and stability (De et al., 2007; Loening et al.,
2006). We compared the BRET2 based MBP sensors incorporating
native RLuc, RLuc2 and RLuc8 (Fig. 2).substrate to 1 mM BRET fusion proteins GFP2–MBP–RLuc, GFP2–MBP–RLuc2 and
.7 mM coelenterazine 400a substrate to 1 mM puriﬁed BRET fusion protein GFP2–
l maltose solution in water (ﬁnal concentration 0.1 mM).
Fig. 3. Effect of 0.1 mM of various sugars on the BRET2 ratio of the GFP2–MBP–
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resulted in enhancements in bioluminescence intensity by factors
of 22 and 29, respectively (Fig. 2A). This is similar in magnitude to
the enhancements (of 28 and 32 (De et al., 2007; Loening et al.,
2006)) previously observed for these substitutions in the absence
of an MBP sensing domain. All further studies therefore used only
the RLuc2 or RLuc8 substituted BRET donors.
The stability of the BRET-MBP fusion protein was not assessed
but we envisage that the construct will be stable under the assay
conditions (pH 7.4, 28 1C, 30 min incubation). The stability of the
individual sensor components have been investigated previously.
MBP is stable in the pH range of 4–10.5 and has a Tm value of
64.9 1C (Ganesh et al., 1997). Fluorescent proteins are extremely
stable as a consequence of their unique 3D structure with wild
type GFP having a Tm of 76 1C (Ward and Bokman, 1982). The
stability of RLuc2 in terms of bioluminescent activity was shown
to have a half-life of more than 3 h when incubated at 37 1C in
serum (Loening et al., 2006).RLuc2 sensor. BRET2 ratio (mean7SD, n¼3) was recorded following addition of
16.7 mM coelenterazine 400a to 1 mM GFP2–MBP–RLuc2 or W140A mutant
(patterned bar) following incubation with water (grey bar) or 0.1 mM of the
stated sugars for 30 min at 28 1C. BRET2 ratios were normalized to the water
response. **Po0.01 and *Po0.05.3.1.2. BRET ratio
BRET ratios were 0.4070.01 (n¼3) for GFP2–MBP–RLuc2 and
0.3970.01 (n¼3) for GFP2–MBP–RLuc8. The estimated distances
between the luciferase and GFP2 in GFP2–MBP–RLuc2 and GFP2–
MBP–RLuc8 in the open conformation are 6.4470.03 nm and
6.5670.03 nm (Dacres et al., 2012b), reasonably consistent with
the 6.9-nm distance measured by FRET (Park et al., 2009). There-
fore, the BRET systems are well matched to this distance with
estimated distances being well within the distance measurement
limit for each BRET system of R0750% (dos Remedios and Moens,
1995) (Fig. S-1, Supporting information).
Only GFP2–MBP–RLuc2 showed any change in BRET2 ratio in
the presence of maltose (Fig. 2B) with an increase in BRET2 ratio
from 0.4070.01 (n¼3) to 0.5170.02 (n¼3). The lack of a
response from GFP2–MBP–RLuc8 could be due to RLuc8 sterically
hindering the access of maltose to its binding site or a deleterious
effect on the ‘‘venus-ﬂy-trap’’ binding site. Comparison of crystal
structures with and without bound maltose suggests that the
change in distance between the N and C termini would result in a
relative movement of RLuc donor to GFP acceptor of only 1 nm,
accompanied by an 81 twist of MBPs N and C lobes relative to each
other. Such a twist has the potential to realign the relative
orientation of the donor/acceptor dipole moments (Sharff et al.,
1992). A change in donor–acceptor separation, or their relative
dipole orientation both affect RET efﬁciency.
3.2. Selectivity
The responses of the BRET2-MBP sensor were measured in the
presence of a range of sugars including mono-, di- and tri-
saccharides (Fig. 3). Only 0.1 mM maltose (P¼0.001) or 0.1 mM
maltotriose (P¼0.02) signiﬁcantly changed the BRET2 ratio. There
was no response to glucose, fructose, sucrose or rafﬁnose. Fehr
et al. (2002) demonstrated that the equivalent FRET biosensor
detected maltose and a range of maltooligosaccharides (MOS) but
did not respond to pentoses, hexoses, disaccharides, trisacchar-
ides or sugar alcohols that do not contain an a-1,4-glucosidic link.
The increase in BRET2 ratio in the presence of 0.1 mM of the
disaccharide maltose was 29.7% but only 17.0% for 0.1 mM
maltotriose, which has three glucose units (Fig. 3). This is
consistent with the observation that MBP cannot close completely
when binding a-1,4-oligomaltosides with more than two sacchar-
ide units as demonstrated by electroparamagnetic resonance
(Hall et al., 1997) and FRET (Fehr et al., 2002).
The W140A loss of function mutant of MBP has a dissociation
constant higher than 100 mM for maltose (Fehr et al., 2002).Introduction of this mutation into the MBP domain of the GFP2–
MBP–RLuc2 sensor completely abolished the BRET2 response to
maltose (Fig. 2). The lack of response of the W140A mutant to
maltose excludes the possibility that the maltose response of
GFP2–MBP–RLuc2 is due to non-speciﬁc interactions with, for
example, the BRET components themselves.
3.3. Sensitivity
The maltose response of the MBP biosensor is concentration
dependent with an EC50 of 0.4 mM (Fig. 4A) and is quasi-linear
over almost three log units ranging from 0.01 mM to 3.2 mM.
The apparent afﬁnity for maltotriose is marginally higher
(EC50¼0.08 mM) despite the restricted closing movement. These
data are consistent with the observation that the binding afﬁnity
of the unmodiﬁed MBP is 1 mM for maltose and 0.16 mM for
maltotriose (Szmelcman et al., 1976). The Hill coefﬁcients of the
maltose and maltotriose concentration response curves (Fig. 4)
are close to unity, being 1.1 and 1.2, respectively. This indicates a
1:1 maltose:MBP interaction consistent with previous FRET
experiments (Fehr et al., 2002), (Medintz et al., 2003a) and our
understanding of PBPs as monomers. The BRET2 responses to
maltotriose have higher variances than the responses to maltose
(Fig. 4A). This is a consequence of the normalization process. The
percentage error, relative to the actual change in BRET ratio, is
similar for both data sets. For example, the BRET2 response to
1107 M sugar is 27.772.6% for maltose and 54.975.9% for
maltotriose, both variances of approximately 10% of the response.
Three FRET-based maltose sensors, FLIPmal sensors, incorpor-
ating mutated MBPs, have afﬁnities for maltose in the range 2.3–
226 mM (Fehr et al., 2002). The FLIPmal variants respond over two
log units, e.g., FLIPmal-2m responds in the range 0.3–21.1 mM
maltose and FLIPmal-25m in the range 2.8–225 mM maltose with
EC50 values of 2.3 mM and 25 mM, respectively. The binding
afﬁnities of the untagged FLIPmal-25m (W230A) and FLIPmal-
225m (W62A) MBP domains were determined as 37 mM and
200 mM, respectively, using the rate of dialysis and ﬂuorescence
quenching (Martineau et al., 1990) method, compared with
25 mM and 226 mM for the corresponding complete nanosensors
as determined by FRET (Fehr et al., 2002). The MBP variant used in
this study (NEB, Australia) incorporates a single point mutation
(A312V). Its binding afﬁnity was determined to be 0.2 mM by
Fig. 4. (A) Sugar concentration dependency of the GFP2–MBP–RLuc2 biosensor response (mean7SD, n¼11), % of maximal BRET2 ratio (BRET2 response (%)) upon addition
of 16.7 mM coelenterazine 400a to 1 mM GFP2–MBP–RLuc2. (B) FRET vs. BRET. Maltose concentration dependency of the BRET2 response (mean7SD, n¼11) of 1 mM GFP2–
MBP–RLuc2 fusion protein upon addition of 16.7 mM coelenterazine 400a compared with the FRET response (mean7SD, n¼3) of FLIPmal-2m (530/485-nm ratio) redrawn
from data of Fehr et al. (2002. BRET2 EC50¼0.4 mM and FRET EC50¼3.2 mM.
Fig. 5. Maltose biosensor response versus beer dilution (mean7SD, n¼3) of 1 mM
GFP2–MBP–RLuc2 fusion protein upon addition of 16.7 mM coelenterazine 400a.
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ing afﬁnity of the BRET2 biosensor of 0.4 mM is the lowest so far
observed for an MBP-based biosensor that is entirely genetically
encoded. It also indicates that incorporation of BRET2 tags did not
markedly perturb the binding afﬁnity.
Comparison of the responses of our BRET2 sensor and FLIPmal-
2m (Fehr et al., 2002) to increasing concentrations of maltose
(Fig. 4B) demonstrates that the former offers more precision and
lower variance. Comparison of data points within the working
concentration ranges of the two sensors highlight this effect with
the BRET2 response to 3.2106 M maltose being 95.472.0% for
BRET2 and 49.377.5% for FRET, with relative errors of 2.1% and
15.3%, respectively. Similarly, the relative errors of the responses
to 1106 M maltose were 1.8% and 21.6% for BRET2 and FRET,
respectively. The difference in the variances follows from the
difference in the maximum change in RET ratio, which is 30% of
the BRET2 signal but only 10% of the FRET signal, in response to
saturating maltose. Given similar absolute levels of experimental
error, the percentage variability in the BRET2 signal is lower.
Due to the higher afﬁnity of the A321V MBP used in this study,
the BRET2 has a lower limit of detection for maltose than the most
sensitive of the FLIPmal biosensors (Fig. 4B) and indeed any
genetically encoded MBP-based biosensor (Fig. S-3 and Table S-
2 in Supporting information). We would expect that incorporation
of the A321V mutation could also lower the limit of detection for
a FLIPmal sensor. The true advantages of the BRET2 system over
FRET relate to its greater precision and potentially broader
operating range, as well as simplicity of measurement. Accord-
ingly, we would expect that incorporating other mutations into
the BRET2-MBP sensor would likely deliver a range of biosensors
with different EC50s but improved precision and working con-
centration ranges.
3.4. Maltose estimation in beer
To test the suitability of the BRET2-based maltose biosensor for
use in complex samples we compared its performance in estimat-
ing maltose concentration in beer with a standard method. Starch
hydrolysis is an important step in brewing and food processing,
with maltose being one of its main products (Enevoldsen, 1978).
Maltose concentration is routinely analysed during brewing as it
is a useful way of monitoring progress of the fermentation.
A 3.5105 dilution of beer was estimated to give 50% of the
maximal BRET2 response (Fig. 5), equivalent to a maltose con-
centration of 0.4 mM (Fig. 4). Therefore, the maltose concentration
in the beer sample was estimated as 10.670.5 mM (n¼3).
An independent estimation using a commercial enzyme-basedassay (Biovision) gave a value of 10.272.1 mM (n¼3) (see
Supporting information for experimental details), which is not
signiﬁcantly different.
In the course of comparing the maltose estimates of the two
methods we were able to directly compare other aspects of the
performance of the BRET-based assay with the maltose assay kit
(see Supporting information). The detection limit of the maltose
assay kit was 3.03 mM (blankþ3 SD of blank) (Fig. S-4) with a
linear range up to 100 mM (Biovision). The BRET2 assay had a
detection limit 10 fold lower than the enzymatic assay. The BRET2
measurement was also much more reproducible (74.7%) than
the commercial maltose assay kit (720.6%). We believe this is
due to the inherent advantages of ratiometric over intensity
measurements.
When MBP-based FRET biosensors were used to quantify
maltose in beer, there was a discrepancy with the results of HPLC
analysis (Fehr et al., 2002). This was attributed to the fact that
HPLC can isolate the maltose peak, whereas MBP-based biosen-
sors also bind maltose oligosaccharides (MOS), such as malto-
triose, which are present in signiﬁcant amounts in beer following
fermentation (Mauri et al., 2002). In this study, our comparator
was an enzymatic assay, which also responds both to maltose and
MOS (Bergmeyer, 1974; Krasikov et al., 2001). The measured
values here are consistent with previous enzymatic measure-
ments of MOS and with determinations using MBP-based electro-
chemical (Benson et al., 2001) and FRET biosensors (Fehr et al.,
2002). The use of ﬂow injection analysis with electrospray mass
spectrometry detection has estimated maltose concentrations in ﬁve
different beers to fall in the range 9.6–12.9 mM (Mauri et al., 2002).
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The limit of detection (LOD) and the EC50 value of a non-
enzymatic biosensor depend on the innate afﬁnity of its receptor
moiety as well as the efﬁciency of transduction coupling, the gain of
the transductionmechanism and its signal-to-noise ratio (Table S-2).
BRET is known to have a better signal-to-noise ratio than FRET, and
theory predicts that BRET2 is better coupled to the MBP, and
potentially other PBPs, than is FRET, therefore, we predicted an
improvement in the dynamic range of the RET signal.
Common analytical methods such as HPLC (Sesta, 2006), gas
chromatography (Garcı´a Ban˜os et al., 2000) and electrospray mass
spectrometry (Mauri et al., 2002), (Rozaklis et al., 2002) can be
used to measure maltose accurately in a variety of different
sample types such as beer (Mauri et al., 2002), food (Sesta,
2006), blood (Rozaklis et al., 2002) and urine (Rozaklis et al.,
2002) but they are generally time-consuming, require expensive
gas/liquid mobile phases and specialized instrumentation. Rela-
tive intensity based FRET biosensors respond to maltose in the
concentration range from 0.26 mM to 2 mM (Fehr et al., 2002). The
use of the same FRET conﬁguration with ﬂuorescent lifetime
measurements resulted in a substantial increase in the LOD and
the EC50 with only maltose concentrations greater than 1.5 mM
being detected (Lee et al., 2011). An alternative FRET transducing
conﬁguration used MBP modiﬁed with cyanine dyes Cy3 or Cy3.5
and b-cyclodextrin conjugated to either cyanine dye Cy5 or the
dark quencher QSY9 (Medintz et al., 2003b) yielding a family of
sensors (Table S-2), one of them exhibiting the highest afﬁnity,
0.14 mM, observed to date. In these cases, b-cyclodextrin binds to
MBP assembling the FRET system. Addition of maltose displaces
b-cyclodextrin resulting in dissociation of the FRET system.
Detectable maltose concentration ranged from 10 nM to 50 mM
(Medintz et al., 2003b). Incorporation of a quantum dot as a donor
into this FRET conﬁguration broadened the maltose detection
range from 7.5 mM to 6.8 mM (Medintz et al., 2005). As with the
CFP/YFP FRET system switching the measurement format from
intensity measurements to lifetime measurements increased the
LOD/ EC50 (Medintz et al., 2005). This indicates that monitoring
lifetime alone may not reﬂect all sensor processes. Only the FRET
system based on b-cyclodextrin/MBP dissociation (Medintz et al.,
2003b) exceeds the sensitivity of the BRET system reported here
(see Fig. S-3 in Supporting information for visual comparison of
simulated dose response curves plotted using afﬁnity data pre-
sented in Table S-2). Unlike our method, the b-cyclodextrin
displacement approach requires the conjugation of organic dyes
to both MBP and b-cyclodextrin. Apart from the added complexity
in preparation and readout, the method cannot be used in intact
cells or for in vivo applications.
As with the FRET biosensors developed by Fehr et al. (2002)
targeted mutation of the MBP domain of the biosensor could be
used to vary the afﬁnity of the biosensor. In this study we used
the same linker sequences (GGTGGG) reported to ﬂank MBP as
introduced by Frommers group (Deuschle et al., 2005) for the
FRET biosensors. It has recently been reported that the signal
intensity of FRET sensors can be signiﬁcantly increased by
optimizing the length and sequences of the linkers (Ha et al.,
2007) highlighting the critical nature of proper orientation of
FRET pairs to achieving highly responsive FRET-based biosensors.
Systematic engineering of linker moieties by inserting and opti-
mizing peptide linkers of different lengths and composition could
enable us to achieve a better coupling of the molecular motion of
the MBP to the BRET2 sensor using RLuc8 as the donor. The RLuc2-
BRET2 sensor is already well coupled to MBP, and it is envisaged it
may not signiﬁcantly beneﬁt from further optimization of linkers.
We have shown that as we predicted substitution of
BRET2 donor and acceptor pairs for FRET reporters in a PBP-basedsensor offers signiﬁcant advantages for sensitivity, precision and
dynamic range. BRET2 transduction could potentially offer the same
advantages for developing sensors for many different analytes by
exploiting the natural diversity of proteins which undergo a ‘‘venus-
ﬂy-trap’’ binding mechanism or by engineering new ligand-binding
speciﬁcities of individual proteins (Looger et al., 2003; Marvin and
Hellinga, 2001). Biosynthesis and work up of the MBP-BRET bio-
sensor uses only routine methods and, based on our sequence, it can
easily be expressed and puriﬁed in any modern molecular biology
laboratory on a scale suitable for conducting experimental investi-
gations. Alternatively, the process could be readily outsourced and
scaled up for industrial use.4. Conclusions
We have demonstrated that BRET is better suited than FRET for
measuring the change in distance induced by maltose binding to
MBP. A BRET-based MBP biosensor responded to maltose and
maltotriose but not other sugars including glucose, sucrose,
fructose and rafﬁnose. A 30% change in BRET2 ratio was induced
by maltose binding, a signiﬁcant improvement in the signal
change exhibited by FRET ratio under similar conditions
(10%). The BRET sensor was sensitive, with an EC50 of 0.37 mM
for maltose and was quasi-linear over three orders of magnitude.
The BRET-MBP biosensor accurately measured maltose in beer
demonstrating its potential suitability for industrial applications
in the fermentation industry. Biosensors for a wide range of
analytes can be developed by exploiting the natural diversity
provided by the PBP superfamily. PBPs undergo a ligand induced
hinge-bending motion. The demonstrated approach would allow
the development of a large family of biosensors capable of
accurately sensing diverse analytes for numerous medical, envir-
onmental and industrial applications.Acknowledgements
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